Purpose: Nearly half of all pregnancies worldwide are unintended. Furthermore, male contraceptives are limited to condoms and vasectomy, which do not provide adequate variety in characteristics to meet the needs of all users.
Male Contraceptive Initiative (MCI), a US-based 501(c)3 nonprofit, is a funding agency and advocate for safe, effective, and reversible contraceptive solutions for sperm-producing people.
Background: The male contraceptive field has matured meaningfully over the past ~5 years. A small, mechanistically diverse number of programs have advanced to clinical-stage development, and a robust pipeline of leads are emerging from academic pursuits. However, several structural challenges remain: limited capacity for follow-through on early academic discovery work, slow progress on promising leads due to lack of specific expertise or fragmented funding, and insufficient capital for a growing field.
MCI’s core grants are the backbone of MCI's research portfolio, designed to maintain field health and continuity. These grants facilitate product development, help projects move from discovery toward defined translational milestones, and emphasize clear go/no-go criteria. Core grants support credible programs that demonstrate strong scientific rationale and a plausible translational trajectory.
For the 2026 cycle, core grants will support programs ranging from discovery through preclinical and clinical development, with clear prioritization given to programs advancing toward translational milestones. This includes projects in hit-to-lead optimization, lead optimization, preclinical development, and IND-enabling studies, while also remaining open to earlier-stage screening and discovery objectives that demonstrate strong alignment with field priorities.
Maximum Award Budget
Up to $400,000 in total costs over a 24-month project period, at a maximum of $200,000 per year.
👉 Off-topic reproductive or general fertility research → low success probability
👉 Key question:
“Will this lead to a viable male contraceptive method?”
👉 Innovation must be practical and scalable
👉 Proposals that clearly address this gap score highly
👉 Overly ambitious or vague proposals are commonly rejected
👉 Evaluation includes:
👉 Applicants engaged in the field have an advantage
👉 Broader impact strengthens applications
👉 Cross-disciplinary innovation improves competitiveness
👉 Clear next-step pathway is important
Highest impact factors:
Moderate predictors:
4. Unmet need relevance
5. Feasibility
6. Early-career development
Supporting factors:
7. Community engagement
8. Interdisciplinary approach
9. Global health relevance
Compared to NIH or general reproductive funders:
👉 Winning formula:
Non-hormonal idea + clear path to real contraceptive + feasible pilot study
✔️ What wins:
❌ What struggles:
This application is open to global academic institutions, for-profit organizations, and other entities. Any individual(s) with the skills, knowledge, and internal or external resources necessary to carry out the proposed research as a Principal Investigator (PI) is invited to submit an application through their institution.
Applicants may submit more than one application, provided that each application is scientifically distinct. Current MCI grantees are eligible to apply for funding through this mechanism. Applicants may submit proposals covering new or existing projects, as long as the work proposed is scientifically distinct from previously funded work. MCI values representation and diversity in the scientific community. Applications from women, people of color, the LGBTQIA community, and other historically marginalized groups are encouraged.
Projects that are not responsive to this announcement include: Approaches developing contraceptives delivered to female users only. Approaches that permanently inhibit fertility or cause sterility. Male or female barrier development (e.g., condoms). Approaches involving administration of steroid hormones to manipulate the hypothalamic–pituitary–gonadal (HPG) axis. Approaches that induce active immunity. Applications focused on molecular targets for which there is no human ortholog. Proposals based on mechanisms that may act post-fertilization. Proposals focused on mechanisms that could only function through administration in the female body (e.g., intrauterine devices, products acting via oviduct or uterus). Applications that are duplicate or highly overlapping with grant awards from other funding agencies.
Proposals better suited to other MCI funding mechanisms may be redirected during review. Applicants with questions regarding eligibility or funding mechanisms are encouraged to contact MCI in advance of developing an application.
Special Invitation - Continued Grants Projects funded by MCI grants that closed out up to 18 months ago or are within 6 months of closeout (as defined by contract period) are eligible for "Continued Grant" consideration. MCI Fellowships are also eligible to "graduate" to a Continued Grant. These applications will be given special consideration at the Letter of Intent stage and are more likely to be invited for full application submission
Sponsor Institute/Organizations: Male Contraceptive Initiative
Sponsor Type: Corporate/Non-Profit
Address: 811 Ninth Street, Suite 120 #255, Durham, NC 27705
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Aug 30, 2026
Aug 30, 2026
$200,000
Affiliation: Male Contraceptive Initiative
Address: 811 Ninth Street, Suite 120 #255, Durham, NC 27705
Website URL: https://www.malecontraceptive.org/uploads/1/3/1/9/131958006/mci_2026_rfa_announcement.pdf
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.